JAMP Pharma Corporation and Angita (AG) Pharma Inc. are recalling all lots of JAMP-Clopidogrel and AG-Clopidogrel 75 mg tablets as some tablets may weigh less or more than they should, meaning patients could unexpectedly receive a lower or higher dose than intended. There may be serious risks associated with the use of an incorrect dose of clopidogrel. Patients taking the affected product should return it to the pharmacy as soon as possible but should not stop their medication until they get a replacement product. Clopidogrel, a prescription drug, is used in adults to help prevent blood clots and reduce the risk of having conditions caused by blood clots such as strokes, unstable angina (chest pain at rest), heart attacks, or peripheral arterial disease (leg pain while walking or at rest) and other circulation problems. It may also be used in adults who have atrial fibrillation (irregular heartbeat). Taking a lower dose than intended can reduce the drug’s effectiveness and may lead to an increased risk of stroke, heart attack, and other serious blood vessel problems. Taking a higher dose than intended can result in an overdose. Signs and symptoms of a clopidogrel overdose may include prolonged bleeding time and subsequent bleeding complications (e.g., nose bleeds, blood in the stool, urine, or eye, vomiting blood, coughing up blood, or a purple spotted rash). Worsening of other side effects such as nausea, vomiting, loss of taste, diarrhea, dizziness, headache, rash, bruising, and joint and/or muscle pain may also occur. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventative actions to stop this issue from reoccurring. The Department will inform the public if any new health risks are identified.
RecallTracker